Global Anesthesia Drugs Market (2020 - 2025) - Mordor Intelligence

SAMPLE – GLOBAL ANESTHESIA DRUGS MARKET11
GLOBAL ANESTHESIA DRUGS MARKET
(2020 - 2025)
Domain: Healthcare Base Year: 2019 Forecast Period: 2020-2025
S A M P L E
Industry Reports | Consulting | Intelligence Center
+1 617 765 2493 | info@mordorintelligence.com | www.mordorintelligence.com
The Study Offers:
• A detailed understanding of the current market dynamics and growth opportunities
• An in-depth analysis of the market size and forecast for the various segments
• An overview of the competitive intelligence, with product innovations and strategies of major players
• Assessment of the COVID-19 impact on the industry

DISCLAIMER
Any information and/or material provided by Mordor Intelligence, including any and all the analysis and/or research from Mordor Intelligence, is provided to a selected
group of customers, in response to orders for such information, material, analysis, and/or research. As a customer of Mordor Intelligence, you acknowledge that our
information, material, and/or services are for your internal use only, and not for any external use and/or dissemination, or general publication, and/or disclosure to any
third parties.
Any and all the information and/or material provided by Mordor Intelligence are based on primary interviews and/or secondary research, and are therefore, subject to
fluctuation and variance. Mordor Intelligence takes no responsibility for any incorrect information and/or material supplied to us by sources we rely on, and no part of
our analysis or research may be given, lent, resold, or disclosed to any third-parties, including non-customers, without explicit or written permission from Mordor
Intelligence.
Unauthorized reproduction and/or transmission of our information, material, analysis, and/or research in any form and by any means, including photocopying,
mechanical/electronic recording, or otherwise, without the explicit and written permission of Mordor Intelligence, is expressly and clearly prohibited.
Any use of the information, material, analysis, and/or research provided by Mordor Intelligence is at your sole risk. You acknowledge that the information, material,
analysis, and/or research is provided “as is” and that Mordor Intelligence provides no warranty of any kind, express or implied, with regard to the information, material,
analysis, and/or research, including but not limited to, merchantability and fitness for any purpose and/or use.

TABLE OF CONTENTS
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Number of Surgeries
4.2.2 New Approvals of Anesthetic Drugs
4.2.3 Reduction in the Cost of Newly Invented Drugs
4.3 Market Restraints
4.3.1 Side Effects of Anesthetic Drugs
4.3.2 Lack of Skilled Anesthetics
4.4 Industry Attractiveness - Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products/Services
4.4.5 Intensity of Competitive Rivalry
4.5 Analyst Perspective - Impact of COVID-19 on the Market
5. MARKET SEGMENTATION
5.1 By Drug Type
5.1.1 General Anesthesia Drugs
5.1.1.1 Propofol
5.1.1.2 Sevoflurane
5.1.1.3 Desflurane
5.1.1.4 Dexmedetomidine
5.1.1.5 Remifentanil
5.1.1.6 Midazolam
5.1.1.7 Other General Anesthesia Drugs
5.1.2 Local Anesthesia Drugs
5.1.2.1 Bupivacaine
5.1.2.2 Ropivacaine
5.1.2.3 Lidocaine
5.1.2.4 Chloroprocaine
5.1.2.5 Prilocaine
5.1.2.6 Benzocaine
5.1.2.7 Other Local Anesthesia Drugs
5.2 By Route of Administration
5.2.1 Inhalation
5.2.2 Injection
5.2.3 Other Routes of Administration
5.3 By Application
5.3.1 General Surgeries

TABLE OF CONTENTS
5.3.2 Plastic Surgery
5.3.3 Cosmetic Surgeries
5.3.4 Dental Surgeries
5.3.5 Other Applications
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPANY PROFILES AND COMPETITIVE LANDSCAPE
6.1 AbbVie Inc.
6.2 Apsen Pharmacare Holdings Limited
6.3 Baxter International Inc.
6.4 B. Braun Melsungen AG
6.5 Fresenius SE & Co. KGaA
6.6 Hikma Pharmaceuticals PLC
6.7 Mylan NV
6.8 Pfizer Inc.
6.9 Piramal Enterprise Ltd
6.10 Teva Pharmaceutical Industries Limited
*List not Exhaustive
**Competitive Landscape Covers – Business Overview, Financials,
Products and Strategies, and Recent Developments
7. MARKET OPPORTUNITIES AND FUTURE TRENDS

5
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

STUDY ASSUMPTIONS AND MARKET DEFINITION
STUDY ASSUMPTIONS MARKET DEFINITION
INTRODUCTION
 The base currency considered is the US Dollar (USD). Conversion of other
currencies to USD is considered based on the average exchange rate for the
respective review period years. The exchange rate conversion for the
forecast period is determined according to the base year’s conversion rates.
 The base year is identified based on the availability of annual reports and
secondary information. The base year considered for this study is 2019.
 The review period considered for this study is from 2014-2018. The CAGR
considered is for the forecast period, 2020-2025. The impact of COVID-19
has been considered in the forecast estimates of the market studied.
 Market size estimations for the forecast years are in real terms. Inflation is
not part of the pricing, and the average selling price (ASP) is kept constant
throughout the forecast period for each country.
 Distribution of primary interviews conducted is based on the regional share
of the market and the presence of key players in each region.
 As a result of data triangulation through multiple methodologies and
approaches, the weighted averages of resulting estimates are considered to
be the final values.
 Anesthesia is one of the most essential components for any surgical
procedure. Anesthesia induces temporary unconsciousness and loss of
protective reflexes. General anesthetic drugs suppress the activities of the
central nervous system and induce a complete lack of sensation.
 Local anesthetics restrict the transmission of nerve impulse from the
targeted region to the spinal cord. Hence, only the targeted region lacks
sensation. Local anesthetics are much safer to use and have fewer side
effects, when compared to general anesthetics.
 The market size can be evaluated by collating the revenues generated from
various segments, along with the costs associated with products and
services.
 The definitions for individual segments have been provided in the respective
segments. The market estimates provided in this report are entirely based
on the segments tracked in this report.
 The estimates provided in this report may not be in line with other reports,
where the segments tracked are not the same as this report.

SCOPE OF THE STUDY
General Anesthesia Drugs
Local Anesthesia Drugs
BY DRUG TYPE
Inhalation
Injection
Other Routes of Administration
BY ROUTE OF
ADMINISTRATION
General Surgeries
Plastic Surgery
Cosmetic Surgeries
Dental Surgeries
Other Applications
BY APPLICATION
North America
Europe
Asia-Pacific
Middle East & Africa
South America
BY GEOGRAPHY
INTRODUCTION

8
2. RESEARCH
METHODOLOGY
2.1 Research Methodology
2.2 Research Phases

RESEARCH METHODOLOGY
■ Mordor Intelligence (MI) advocates an appropriate mix of secondary and primary researches to meet clients’ objectives.
■ MI translates market insights (market dynamics, competition, varying consumer demands, and regulations) into actionable business insights.
■ The following phases are practiced at Mordor for efficient delivery of various syndicated and consulting assignments:
STEP 1
SCOPING/PROJECT INITIATION
STEP 2
MARKET ANALYSIS
STEP 3
PROJECT DELIVERY
Decipher client requirements/market to be
studied
Tailor-made research approach for
customized reports
Effective use of Mordor’s knowledge
repository to gather relevant insights
Confirm the objectives of the assignment with
the client
Extensive desk research to identify most relevant secondary information available
Contact Mordor’s empaneled experts and identify industry experts across the market
Conduct primaries and surveys to gather qualitative and quantitative insights
Triangulate and analyze data to finalize actionable business insights
Finalize report contents and establish
a deliverable format
Report delivery with high-quality market insights, competitive landscape, etc.,
as per the proposed content.

RESEARCH PHASES EXPLAINED
SECONDARY RESEARCH PRIMARY RESEARCH
This phase involves a thorough synthesis of existing publications across the web
to gather meaningful insights on the current situation of the market, technology
developments, and any other market-related information. The sources include,
but are not limited to:
◼ Scientific papers, journals, and publications.
◼ Trade information to understand imports, exports, and average traded price
of the commodity, if available.
◼ Industry and government websites for blogs, magazines, and other
publications.
◼ Conference proceedings and association publications.
◼ Investor presentations, technical brochures, annual reports, press releases,
transcripts of key personnel interviews, and other strategic publications by
several competitors in the market.
◼ Product information, including technical specifications, approvals, patents, etc.
◼ Public sources/healthcare reports (OECD, CDC, etc.)
◼ Paid sources (Questel Orbit, Factiva, Bloomberg, Seeking Alpha, etc.)
◼ Other sources, including journals, articles, etc. (for prices and usage patterns)
◼ At Mordor, we pool in industry experts across the value chain to gather first-hand
insights on the market studied. In addition to these knowledgeable industry
veterans or retired experts, consultants and freelancers are a call away to
collaborate with Mordor on any assignment that requires real-time industry
insights.
◼ MI is also equipped to conduct market surveys to gather qualitative insights and
the opinion of individuals related to the industry.
▪ Primary research is used both to validate the data points obtained from
secondary research and to fill the data gaps after secondary research. Data
gathered during the primary research phase are useful to arrive at critical
insights, both qualitative and quantitative. These insights can be used to
ascertain the following:
• Critical market dynamics (drivers, restraints, future, and regulations) and
their impact.
• Market distribution across various segments.
• Market entry for new companies and insights on the competitive
landscape.
MODES OF PRIMARY RESEARCH
Telephonic
Interviews
Email
Interviews
Chat
Interviews
Virtual
Council
Surveys
•and Other
Modes of
Primary
Research

RESEARCH PHASES EXPLAINED
DATA TRIANGULATION AND INSIGHT GENERATION
◼ Based on the factors (both endogenous and exogenous in nature) identified and collected during the secondary and primary phases, our in-house subject matter
experts transform the quantitative data extracted and use them to infer critical insights.
◼ The market size estimations are carried out through ‘bottom-up’ and ‘top-down’ approaches.
◼ Our top-down and bottom-up approaches are integrated into our ‘In-house Model Sheets’, which are used to generate the market estimates and growth rates
(depending upon the historical trends of the respective markets, along with various factors, such as drivers, restraints, and recent developments in the market) of the
product segment in the respective country.
It is a process of combining outcomes from different sources to increase the
validity and reliability of the results. This process also helps strengthen
conclusions about findings and reduce the risk of false interpretations. The
insights obtained from both secondary and primary research are analyzed and
validated by the process of data triangulation to arrive at closer estimates.
An econometric model is a simplified representation of a real-world process.
Here, the tools of econometric theory are used to analyze and forecast
economic phenomenon and to solve unknown quantities, such as forecast
demand, supply, investment, production, consumption, etc.
After the data is curated, analysts populate the report. From data and forecast,
insights are drawn to visualize the entire ecosystem in a single report.
DATA
TRIANGULATION
ECONOMETRIC
MODELING
REPORT
WRITING

12
4. MARKET
DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Industry Attractiveness - Porter’s Five Forces
Analysis

Impact
MarketDriversMarketRestraints
Impact
Low
High
Low
High
MARKET DRIVERS AND RESTRAINTS
MARKET DYNAMICS
REDUCTION IN THE COST OF
NEWLY INVENTED DRUGS
SIDE EFFECTS OF ANESTHETIC
DRUGS
INCREASING NUMBER OF
SURGERIES
LACK OF SKILLED ANESTHETICS
NEW APPROVALS OF
ANESTHETIC DRUGS

MARKET DRIVERS
MARKET DYNAMICS
▪ Increasing number of surgeries and emergency cases are the main factors that are driving the growth of the global anesthesia drugs market. Anesthetic drugs are used
for accident care, like inducing anesthesia through the intravenous route of administration, which is not an easy task in ambulatory settings. In emergency labors, rapid
sequence induction of general anesthesia is performed via tracheal intubation. In such conditions where administration of intravenous anesthesia is not possible, these
drugs come to the rescue, and in recent years, the demand for these has increased.
▪ According to the Royal College of Physicians, in 2018, hip fracture is the most common serious injury among older people, and the reason to need emergency
anesthesia/surgery, and also the cause of accidental death. In 2017-2018, almost 59,000 people aged 65+ experienced a hip fracture in the United Kingdom.
▪ As per the Organization for Economic Co-operation and Development (OECD) stats, in Canada, the number of surgeries performed was 378,448 during 2013, and it
increased to 396,218 in 2017. In France, surgeries performed in 2014 were 773,308, and they increased to 863,837 in 2017. Thus, the rising number of surgical procedures
is expected to increase the demand for anesthesia drugs.
▪ According to the All India Institute of Medical Science (AIIMS), it performed 1.94 lakh surgeries in India, in 2018, recording the highest number of surgeries performed
across the world in that same year.
▪ According to the American Society of Plastic Surgeons, 17.7 million cosmetic procedures, 1.8 million cosmetic surgical procedures, 15.9 million cosmetic minimally-
invasive procedures, and 5.8 million reconstructive procedures were performed in 2018, in the United States.
▪ In Europe, an increasing number of surgeries are being performed for the cases of cataract, tonsillectomy, colonoscopy, caesarean sections, and hip replacements. It was
found that, around 1.4 million caesarean sections were performed in Europe, in 2017, as per the Eurostat data.
▪ Thus, owing to the rising number of surgeries across the world, the global anesthesia drugs market is expected to grow significantly during the forecast period.
▪ However, due to the cancellation and postponing of many elective surgeries owing to COVID 19 pandemic, the number of surgeries decreased drastically in the year 2020
hitting the market with a little negative impact.
INCREASING NUMBER OF SURGERIES
----------- (Detailed Analysis Available in the Full Report) ----------

MARKET RESTRAINTS
MARKET DYNAMICS
▪ Anesthetic drugs cause several side effects, including nausea, vomiting, dry mouth, sore throat, shivering, muscle aches, disorientation, itching, sleepiness, and mild
hoarseness.
▪ Anesthetic gases may produce several varied changes in the patient's mental status after surgery, such as emergence of excitement and delirium. It is very important that
the healthcare professionals be aware of the risk of perioperative myocardial infarction in patients with pre-existing heart diseases, if early detection and treatment are to
occur.
▪ Inhalational anesthetics cause respiratory depression, a decrease in arterial blood pressure and cerebral metabolic demand, and an increase in cerebral blood flow. Side
effects differ based on the substance, for example, halothane can cause hepatotoxicity. The common side effects include temporary confusion and memory loss (more
common in the elderly), dizziness, difficulty in urinating, nausea and vomiting, shivering, and sore throat due to the breathing tube.
▪ Moreover, older adults and those undergoing lengthy procedures are the most at risk of negative outcomes. These outcomes can include postoperative confusion, heart
attack, pneumonia, and stroke. Other conditions, including obstructive sleep apnea, seizures, existing heart, kidney or lung conditions, high blood pressure, alcoholism,
smoking, history of reactions to anesthesia, medications that can increase bleeding like aspirin, drug allergies, diabetes, and obesity or overweight can also increase the
risk for the side effects.
▪ Unintended intraoperative awareness is another side effect, which refers to rare cases (1 in every 19,000 patients), where patients report a state of awareness during an
operation, after the point at which the anesthetic should have removed all sensation. Some patients are conscious about the procedure itself and some can even feel pain.
▪ So, these complications associated with the use of anesthesia are expected to hinder the growth of the market globally.
SIDE EFFECTS OF ANESTHETIC DRUGS

PORTER’S FIVE FORCES ANALYSIS
THREAT OF NEW ENTRANTS
BARGAINING
POWER OF
SUPPLIERS
BARGAINING
POWER OF BUYERS
THREAT OF
SUBSTITUTE
PRODUCTS/
SERVICES
INTENSITY OF
COMPETITIVE
RIVALRY
DESCRIPTION
The threat of new entrants is XX.
The bargaining power of buyers is XX.
The bargaining power of suppliers is XX.
The threat of substitute products/services is XX.
The intensity of competitive rivalry is XX.
MARKET DYNAMICS

PORTER’S FIVE FORCES ANALYSIS
PORTER’S FIVE FORCES ANALYSIS OVERALL RATING
THREAT OF NEW
ENTRANTS • XX XX
BARGAINING POWER
OF BUYERS • XX XX
BARGAINING POWER
OF SUPPLIERS • XX XX
THREAT OF SUBSTITUTE
PRODUCTS/SERVICES • XX XX
INTENSITY OF
COMPETITIVE RIVALRY • XX XX
MARKET DYNAMICS

2017 2018 2019 2020 2021 2022 2023 2024 2025
Estimates Without the Effect of COVID-19 Market Size (Considering the Impact of COVID - 19)
SAMPLE FIGURE
Source: Mordor Intelligence
ANESTHESIA DRUGS MARKET
Revenue in USD million, Global, 2017-2025
CAGR
XX%
IMPACT OF COVID-19 ON THE MARKET
MARKET DYNAMICS

■ In recent times, many countries around the world are facing a huge threat of COVID–19 (coronavirus). The World Health Organization (WHO) listed it as a potential global health
threat due to the high mortality rate. There is no treatment available against this type of disease. Most pharmaceutical and biotechnological companies are focusing on their R&D
departments to identify new molecules or leads for the treatment of this disease.
■ According World Health Organization, as of July 22, 2020, there are about 14,765,256 confirmed cases of COVID-19, with more than 612,054 deaths, while it spread over 216
countries.
■ Moreover, according to the WHO, the number of secondary infections generated from one infected person is between 2 to 2.5 for COVID-19. Therefore, on an average, one
person transmits to two other people, leading to an exponential increase in the number of affected cases.
■ Healthcare facilities, such as hospitals and diagnostic centers, are investing heavily in maintaining the supply of essential equipment and drugs. Most diagnostic manufacturers are
focusing on the development of fast and technologically advanced diagnostic tests. Medical equipment and pharmaceutical companies are utilizing their R&D and manufacturing
facilities to develop and manufacture the essential products.
■ The manufacturing industry has been hit hard in many ways by the Corona effect. Initially, low production, hits the manufacturing companies due to low offtake. This takes some
time to prove itself, as, some distributors, seeing an opportunity to make a profit in the event of a growing shortage, tend to continue to sell, but with an extended reduction
payment system. The pharmaceuticals had stopped the production of products due to the lack of labor and raw material, which is hindered due to the lockdown that is placed
globally.
■ The uncertainties in logistics leads to a cascading effect. Transporters struggle to place vehicles for loading and are under pressure to adjust their quotes for carrying goods, as
they also face lower attendance, with their operational risks increasing steeply.
■ Moreover, due to the increasing cases of COVID-19, all hospitals, globally, have cancelled scheduled and elective surgeries. Acute surgical emergencies are still inevitable and are
being addressed in a timely and sensible manner. According to the report published by British Journal of Surgery, on May 12, 2020, estimated 585,000 elective surgeries were
postponed in the 12-week lockdown in India alone, and 28.4 million elective surgeries worldwide are expected to be canceled or postponed.
■ However, many companies started production and launches of novel anesthesia products to maintain the demand supply chain.
MARKET DYNAMICS

MARKET DYNAMICS

21
5. MARKET
SEGMENTATION
5.1 By Drug Type
5.2 By Route of Administration
5.3 By Application
5.4 By Geography

5.1.1 General Anesthesia Drugs
5.1.2 Local Anesthesia Drugs
5.1 BY DRUG TYPE

BY DRUG TYPE
MARKET SEGMENTATION
General Anesthesia Drugs Local Anesthesia Drugs
Revenue Share (%), by Drug Type, Global, 2019
Revenue in USD million, by Drug Type, Global, 2017-2025
Drug Type 2017 2018 2019 2020 2025
CAGR
(%)
General Anesthesia Drugs XX XX XX XX XX XX
Local Anesthesia Drugs XX XX XX XX XX XX
SAMPLE FIGURE

5.1.1.1 Propofol
5.1.1.2 Sevoflurane
5.1.1.3 Desflurane
5.1.1.4 Dexmedetomidine
5.1.1.5 Remifentanil
5.1.1.6 Midazolam
5.1.1.7 Other General Anesthesia Drugs
5.1.1 GENERAL ANESTHESIA
DRUGS

BY GENERAL ANESTHESIA DRUGS
MARKET SEGMENTATION - DRUG TYPE
Propofol
Sevoflurane
Desflurane
Dexmedetomidine
Remifentanil
Midazolam
Other General
Anesthesia Drugs
Revenue Share (%), by General Anesthesia Drugs, Global, 2019
Revenue in USD million, by General Anesthesia Drugs, Global, 2017-2025
SAMPLE FIGURE
General
Anesthesia Drugs
2017 2018 2019 2020 2025 CAGR (%)
Propofol XX XX XX XX XX XX
Sevoflurane XX XX XX XX XX XX
Desflurane XX XX XX XX XX XX
Dexmedetomidine XX XX XX XX XX XX
Remifentanil XX XX XX XX XX XX
Midazolam XX XX XX XX XX XX
Other General
Anesthesia Drugs
XX XX XX XX XX XX

PROPOFOL
2017 2018 2019 2020 2025
Year
SAMPLE FIGURE
 The increasing incidences of emergency surgeries, growing geriatric population, extensive usage of
the drug, short-acting characteristics, and a growing number of surgical procedures worldwide, are
the major factors propelling the growth of the global anesthesia drugs market.
 Propofol is an intravenous anesthetic agent used for induction and maintenance of general
anesthesia. IV administration of propofol is used to induce unconsciousness after which anesthesia
may be maintained using a combination of medications.
 Propofol is also used for induction and/or maintenance of anesthesia and for management of
refractory status epilepticus.
 The drug has been used for a long time for various surgical procedures requiring anesthesia. Teva
Pharmaceuticals had stopped manufacturing Propofol for certain time. However, the drug returned
to the market in 2013.
 Moreover, due to the high demand for drugs, various manufacturers around the world are actively
manufacturing generics and marketing to expand their market share.
 In January 2019, Dr Reddy's Laboratories launched Propofol Injectable Emulsion, used for the
induction of general anesthesia and sedation in intensive care units, in the United States.
 Even in the wake of the COVID-19 epidemic, Hikma Pharmaceuticals PLC introduced Propofol
Injectable Emulsion (April 2020), for sedation and anesthesia, for intubated, mechanically ventilated
adults in the Intensive Care Unit, to surpass the increase in the demand due to a rise in patients in
hospitals, resulting from the COVID-19 pandemic.
 Thus, owing to the aforementioned factors, the propofol segment is expected to witness a healthy
CAGR over the forecast period.
Revenue in USD million, Propofol, Global, 2017-2025
---------- (Detailed Analysis Available in the Full Report) ----------
CAGR
XX%
MARKET SEGMENTATION – BY PRODUCT TYPE - BY GENERAL ANESTHESIA DRUGS

27
5.4 GEOGRAPHY
5.4.1 North America
5.4.2 Europe
5.4.3 Asia-Pacific
5.4.4 Middle East & Africa
5.4.5 South America

BY GEOGRAPHY
MARKET SEGMENTATION
North America Europe
Asia-Pacific Middle East & Africa
South America
Revenue Share (%), by Geography, Global, 2019
Revenue in USD million, by Geography, Global, 2017-2025
Geography 2017 2018 2019 2020 2025 CAGR (%)
North America XX XX XX XX XX XX
Europe XX XX XX XX XX XX
Asia-Pacific XX XX XX XX XX XX
Middle East &
Africa
XX XX XX XX XX XX
South America XX XX XX XX XX XX
SAMPLE FIGURE

29
5.4.2 EUROPE
5.4.2.1 United Kingdom
5.4.2.2 Germany
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe

EUROPE
MARKET SEGMENTATION – BY GEOGRAPHY
Revenue Share (%), by Country, Europe, 2019
Revenue in USD million, by Country, Europe, 2017-2025
Country 2017 2018 2019 2020 2025 CAGR (%)
United Kingdom XX XX XX XX XX XX
Germany XX XX XX XX XX XX
France XX XX XX XX XX XX
Italy XX XX XX XX XX XX
Spain XX XX XX XX XX XX
Rest of Europe XX XX XX XX XX XX
United Kingdom Germany France Italy Spain Rest of Europe
SAMPLE FIGURE
---------- (Detailed Analysis Available in the Full Report) ----------

■ Owing to the increase in the number of surgical procedures for cardiovascular ailments, orthopedics,
hernia, and other forms of general surgery, there is a growth in the UK anesthesia drugs market.
■ According to the OECD statistics, during 2017, it was estimated that around 4.8 million surgical admissions
were recorded in the United Kingdom. In 2017, hernia operation, hip replacement, and knee replacement
were the most common surgical procedures recorded, all of which involve the use of inhaled anesthesia
through devices, along with IV anesthesia drugs.
■ The market for anesthesia drugs in the region is also being driven by the major companies launching their
products in the European region. For instance, Piramal Group launched Sevoflurane in European countries
in early 2019. Furthermore, Halothane, a drug from Piramal Group is not sold for pediatric purpose outside
the United Kingdom. This indicates that the United Kingdom has gained the attention of such big players.
■ It has been observed that around 80% of the population seeks healthcare for spinal pain at some point in
their lives in the United Kingdom. As per the British Spine Registry Annual Report Year Ending December
2018, in 2017-2018, there were 58,590 recorded NHS spinal procedures in the United Kingdom. The
number of people seeking treatments for spinal surgeries is expected to rise, given the aging population,
increasing obesity, and decreased physical activities. This, in turn, is expected to increase the growth of the
UK anesthesia drugs market over the forecast period.
■ However, the National Health Service advised hospitals to cancel most elective surgeries for 12 weeks. It is
estimated that this will result in 516,000 cancelled surgeries, including 36,000 cancer procedures in the
United Kingdom. Though there is stagnation in the growth for this year, all the backlogs of the surgeries
will be cleared after the COVID 19 disruption ends, leading to a hike in the growth.
UNITED KINGDOM
MARKET SEGMENTATION – EUROPE
2017 2018 2019 2020 2025
Year
SAMPLE FIGURE
Revenue in USD million, United Kingdom, 2017-2025
CAGR
XX%

32
6. COMPETITIVE
LANDSCAPE
6.1 AbbVie Inc.
6.2 Apsen Pharmacare Holdings Limited
6.3 Baxter International Inc.
6.4 B. Braun Melsungen AG
6.5 Fresenius SE & Co. KGaA
6.6 Hikma Pharmaceuticals PLC
6.7 Mylan NV
6.8 Pfizer Inc.
6.9 Piramal Enterprise Ltd
6.10 Teva Pharmaceutical Industries Limited

USD 51,750 million
Revenue
Founded in 1849
New York, United States
www.pfizer.com
+ 212 733-2323
Source: Mordor Intelligence
PFIZER INC.
Revenue in USD million, 2017-2019
52,546
53,647
51,750
2017 2018 2019
■ Pfizer Inc. is a biopharmaceutical company that discovers, develops, manufactures, and sells
healthcare products, worldwide. The company operates through the Global Innovative
Pharmaceutical (GIP), Global Vaccines, Oncology, and Consumer Healthcare (VOC), and Global
Established Pharmaceutical (GEP) segments.
■ It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual
provider offices, and the Centers for Disease Control and Prevention.
■ It is primarily focusing on the R&D of biosimilars, inflammation and immunology, metabolic
diseases and cardiovascular risks, neuroscience, oncology, rare diseases, and vaccines.
■ The company operates in two business segments, which include Innovative Health (focuses on
developing and commercializing novel, value-creating medicines, and vaccines) and Essential
Health (engages in targeted business development to enable its commercial strategies).
PFIZER INC. – OVERVIEW
COMPANY PROFILES AND COMPETITIVE LANDSCAPE
~88,300
Employees

■ In 2019, the company’s total revenue decreased to USD 51,750 million, which
was USD 53,647 million in 2018.
■ Foreign exchange and interest rate risk decreased the revenue to a larger
extent. 54% of the total 2019 revenues were derived from international
operations, including 21% from Europe and 24% from China, Japan, and the
Rest of Asia. As it operates in multiple foreign currencies, including the Euro,
the Chinese Renminbi, the Japanese Yen, the Canadian Dollar, the UK Pound,
and approximately 100 other currencies, changes in these currencies relative
to the US Dollar will impact its revenues and expenses
■ The key therapeutic areas, including the company’s Innovative Health (IHP)
segment, are internal medicine, vaccines, oncology, inflammation and
immunology, rare diseases, and consumer healthcare.
76.2%
19.8%
4.1%
Biopharma
Upjohn
Consumer Healthcare
PFIZER INC. – SEGMENTS
■ Higher revenue from continued growth of anti-infective products in China is
driven by the increased demand for Sulperazon and new launches. The 2018
US launches of immune globulin intravenous products (Panzyga and
Octagam) and certain anti-infectives products (Zavicefta, Zinforo, and
Cresemba) in the international developed and emerging markets also
contributed to the growth.
■ The Developed European region includes markets, such as Western Europe,
Scandinavian countries, and Finland. The Developed Rest of the region
includes Japan, Canada, South Korea, and Australia & New Zealand.
■ The Emerging Markets region includes, but is not limited to, Asia (excluding
Japan and South Korea), Latin America, Eastern Europe, Middle East & Africa,
Central Europe, and Turkey.
46%
54%
United States
International
PFIZER INC.
Revenue Breakdown (%), by Business Segment, 2019
PFIZER INC.
Revenue Breakdown (%), by Geography, 2019

ACQUISITIONSTECHNOLOGIES
◼ Marcaine Spinal
◼ XX
◼ XX
*List not Exhaustive
■ The company’s strategy is to minimize the adverse impact on its revenues, work within the current legal and
pricing structures, and continue to review its pricing arrangements and contracting methods with the payers,
to maximize patient access.
■ It collaborates with healthcare providers, governments, and local communities to support and expand the
access to reliable and affordable healthcare worldwide.
■ Its Innovative Health segment focuses on developing and commercializing novel value-creating medicines and
vaccines, while the Essential Health segment engages in targeted business development, to enable its
commercial strategies.
■ Its global portfolio includes medicines and vaccines and many of the world’s best-known consumer healthcare
products. The company works across the developed and emerging markets to advance wellness, prevention,
treatments, and cures that challenge the most feared diseases.
■ The company’s strategies also include the active management of its portfolio, maximizing the growth of core
product segments, acquisitions to strengthen the core areas of its portfolio (such as its recent acquisition of
AstraZeneca’s small molecule anti-infective business), and divestitures to increase focus on its core strengths.
PRODUCTS AND SERVICES STRATEGIES
PFIZER INC. – PRODUCTS AND STRATEGIES
PRODUCTS
--- (Detailed Analysis Available in the Full Report)---

PFIZER INC. - RECENT DEVELOPMENTS
XXX
XX
M
M I E PMerger and Acquisition Product Innovation Expansion Partnership
Pfizer acquired Array, a commercial stage
biopharmaceutical company focused on the
discovery, development, and commercialization
of targeted small molecule medicines, to treat
cancer and other diseases.
JUL 2019
M
--- (Detailed Analysis Available in the Full Report)---

FOR MORE INFORMATION,
PLEASE CONTACT
5th Floor, Brigade Towers, Financial District,
Gachibowli, Hyderabad – 500032, India
+1 617-765-2493
info@mordorintelligence.com www.mordorintelligence.com
Industry Reports | Consulting | Intelligence Center
+1 617 765 2493 | info@mordorintelligence.com | www.mordorintelligence.com

Global Anesthesia Drugs Market (2020 - 2025) - Mordor Intelligence

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Global Anesthesia Drugs Market (2020 - 2025) - Mordor Intelligence

Similar to Global Anesthesia Drugs Market (2020 - 2025) - Mordor Intelligence (20)

Recently uploaded

Recently uploaded (20)

Global Anesthesia Drugs Market (2020 - 2025) - Mordor Intelligence